Hindustan Laboratories, a maker of generic medicines, is preparing its first public offering to raise money for the business.
What the IPO Looks Like
The company will issue 5 million new shares and the promoter will sell another 9.1 million shares. This mix of fresh issuance and promoter sale is called an "Offer for Sale" (OFS).
Why the Funds Are Needed
Proceeds from the IPO will mainly be used for working‑capital needs such as buying raw materials, paying staff and covering day‑to‑day expenses, as well as other general corporate purposes.
Company Background
Hindustan Laboratories is an Indian pharmaceutical firm that makes generic drugs for government hospitals and health programs. In the six months ending September 30, 2025, it supplied medicines to all 27 Indian states and Union Territories.
Product Portfolio
- Anti‑allergic and anti‑diabetic medicines
- Anti‑infectives, anti‑malarial and antiparasitic drugs
- Blood‑related and cardiac medicines
- Gastro‑intestinal treatments
- Keratolytic and pain‑relief products
- Respiratory, vitamin and mineral supplements
Lead Manager
Choice Capital Advisors has been appointed as the book‑running lead manager for the issue.
What Retail Investors Should Know
The IPO gives individual investors a chance to own a piece of a growing pharma company that already has a wide reach across India’s public health system. As with any new listing, potential investors should review the prospectus carefully and consider the company’s growth prospects, competitive landscape, and financial health before deciding.
Remember, this is perspective, not prediction. Do your own research and consider your risk tolerance before investing.